Efgartigimod / Hyaluronidase
Vyvgart Hytrulo is a subcutaneous formulation of efgartigimod alfa-fcab, an FcRn antagonist designed to reduce pathogenic immunoglobulin G (IgG) antibodies. It is specifically indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. By targeting the neonatal Fc receptor, this medication helps alleviate the muscle weakness and fatigue characteristic of myasthenia gravis.
Vyvgart Hytrulo is an FcRn antagonist injection used to treat generalized myasthenia gravis by reducing pathogenic IgG antibodies.
Key facts at a glance
- RxNorm
- 2639953
- Generic
- Vyvgart Hytrulo
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Vyvgart Hytrulo is indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. It helps improve daily functioning and reduces symptom severity in patients with this autoimmune neuromuscular disorder.
Vyvgart Hytrulo contains efgartigimod alfa-fcab, which is an FcRn antagonist. It works by binding to the neonatal Fc receptor (FcRn), which prevents IgG antibodies from being recycled and leads to their degradation. This reduces the levels of pathogenic IgG antibodies, including anti-AChR antibodies that attack neuromuscular junctions, thereby alleviating myasthenia gravis symptoms.
Vyvgart Hytrulo is administered as a subcutaneous injection, typically given weekly for 4-week cycles. Common side effects may include respiratory tract infections and headaches. Patients should be monitored for infections during treatment. This medication should only be used under the supervision of a healthcare provider experienced in managing myasthenia gravis.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy